Novo Nordisk to slash prices of weightloss drugs in US / Photo: © GETTY IMAGES NORTH AMERICA/AFP/File
RIO
-0.3300
The Fort Worth Press - Novo Nordisk to slash prices of weightloss drugs in US
USD
-
AED 3.673008
AFN 64.503214
ALL 80.819685
AMD 361.405228
ANG 1.789785
AOA 917.000132
ARS 1525.743205
AUD 1.42204
AWG 1.80125
AZN 1.694926
BAM 1.741787
BBD 2.015015
BDT 123.745402
BGN 1.747831
BHD 0.377604
BIF 3000.997453
BMD 1
BND 1.278059
BOB 11.730759
BRL 5.0336
BSD 1.000472
BTN 94.559477
BWP 13.70595
BYN 2.971479
BYR 19600
BZD 2.012094
CAD 1.40468
CDF 2315.999614
CHF 0.823985
CLF 0.02484
CLP 977.639757
CNY 6.67805
CNH 6.673855
COP 3194.48
CRC 455.529135
CUC 1
CUP 24.010794
CVE 98.199695
CZK 21.58565
DJF 177.720049
DKK 6.651515
DOP 61.440772
DZD 134.600855
EGP 54.383604
ERN 15
ETB 163.87083
EUR 0.88984
FJD 2.253797
FKP 0.747587
GBP 0.74635
GEL 2.589651
GGP 0.747587
GHS 11.660299
GIP 0.747587
GMD 73.49688
GNF 8854.987666
GTQ 7.645587
GYD 209.311853
HKD 7.846885
HNL 26.857072
HRK 6.703799
HTG 131.084908
HUF 325.065498
IDR 18027.05
ILS 3.088402
IMP 0.747587
INR 94.43255
IQD 1516.6493
IRR 1832374.999738
ISK 121.269746
JEP 0.747587
JMD 158.780625
JOD 0.709015
JPY 158.134988
KES 129.859579
KGS 87.449845
KHR 4068.146802
KMF 439.503571
KPW 899.999961
KRW 1325.979763
KWD 0.31018
KYD 0.833753
KZT 446.890557
LAK 22518.390538
LBP 89591.044298
LKR 332.14739
LRD 170.580744
LSL 16.412051
LTL 2.95274
LVL 0.60489
LYD 6.419294
MAD 9.819615
MDL 17.998442
MGA 4521.489767
MKD 54.903951
MMK 2099.21541
MNT 3597.533576
MOP 8.085932
MRU 40.128421
MUR 47.319959
MVR 15.459751
MWK 1734.751129
MXN 18.645615
MYR 4.081198
MZN 63.902977
NAD 16.412051
NGN 1331.830194
NIO 36.816372
NOK 9.371645
NPR 151.295341
NZD 1.75332
OMR 0.384501
PAB 1.000481
PEN 3.438421
PGK 4.479652
PHP 63.399499
PKR 276.89823
PLN 3.87625
PYG 5756.677086
QAR 3.647261
RON 4.753003
RSD 104.53802
RUB 82.104013
RWF 1478.615162
SAR 3.748965
SBD 8.07458
SCR 13.97401
SDG 601.492558
SEK 9.878845
SGD 1.27707
SHP 0.7473
SLE 23.919966
SLL 20969.504398
SOS 571.749178
SRD 37.735499
STD 20697.981008
STN 21.819089
SVC 8.754392
SYP 13001.999685
SZL 16.418788
THB 33.570497
TJS 9.214157
TMT 3.51
TND 2.986543
TOP 2.40776
TRY 49.598465
TTD 6.792416
TWD 32.411301
TZS 2644.999678
UAH 45.047334
UGX 4207.076509
UYU 40.164934
UZS 11975.562621
VES 879.788897
VND 25856.5
VUV 119.136032
WST 2.774679
XAF 583.696876
XAG 0.017313
XAU 0.000241628771
XCD 2.70255
XCG 1.803058
XDR 0.707052
XOF 583.696876
XPF 106.20998
YER 236.101147
ZAR 16.360597
ZMK 9001.202969
ZMW 20.069287
ZWL 321.999592
SSP 5787.554334
MXV 2.10465
- Carrick unconcerned over future despite 'unacceptable' Como loss
- Villa tame Viking to stay perfect in Champions League
- Real Madrid rout Leipzig to continue perfect European start
- Tesla profits drop but top analyst estimates
- Walmart welcomes AI agents as Anthropic launches its own
- Angels drop Suzuki as manager after club's worst MLB season
- Quebec separatist premier sworn in without royal presence
- Washington orders US embassy staff, families to leave Saudi Arabia
- UAE nominates official to lead UN
- Musk's SpaceX results lift global stock markets
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
W.Lane--TFWP
